The U.S. cellular immunotherapy market size surpassed USD 11,307 million in 2024 and is predicted to reach around USD 86,043 million by 2034, registering a CAGR of 22.5% from 2025 to 2034.
The U.S. cellular immunotherapy market refers to the production, distribution, and application of cellular immunotherapy which is also known as adoptive cell therapy, which is a form of treatment that uses the cells of our immune system to eliminate cancer. Cellular immunotherapy is a type of immunotherapy in which T cells (which are a type of immune cell) are given to a patient to help the body fight diseases, such as cancer. Cancer immunotherapy offers the possibility for long-term control of cancer.
Immunotherapy can train the immune system to remember cancer cells. This immune memory may result in longer-lasting and potentially permanent protection against cancer recurrence. On a basic level, immunotherapy works in one of two ways. It can boost the mechanisms of the immune system so that it has more strength to fight cancer cells. Or it can target or destroy specific proteins, or receptors, on cancer cells to prevent them from outsmarting the immune system. Immunotherapy for cancer uses our body’s immune system to find and destroy cancerous cells. Immunotherapy also helps some people with cancer to live longer.
Personalized medicine and biomarker development driving the growth of the U.S. cellular immunotherapy market. Cancer immunotherapies, which target neoantigens, may lead to a precise treatment for cancer patients, despite the challenge of accurately predicting neoantigens that can induce cytotoxic cells in individual patients. There are many potential benefits of personalized medicine, including minimizing the risk of drug toxicity, increasing the advantages of the medicines used, contributing to the balance of the healthcare system, and facilitating drug discovery and development programs. Personalized medicine is at the heart of immunotherapy, currently one of the hottest areas of cancer research.
| Industry Worth | Details |
| Market Size in 2024 | USD 11,307 Million |
| Market Size in 2025 | USD 13,851 Million |
| Market Size by 2034 | USD 86,043 Million |
| Market Growth Rate from 2025 to 2034 | CAGR of 22.5% |
Immunotherapy is a new approach that harnesses the power of our immune systems to identify and control diseases like cancer. Biomarkers for cellular immunotherapy can help doctors to choose the best treatment for cancer patients. Immunological biomarkers such as immune activation markers, soluble forms of cell receptors, adipocytokines, chemokines, and serum cytokines can act as surrogate markers for cellular activation and play a key role in the function of the immune system. Biomarkers can help in disease understanding and communication by objectively portraying changes in disease status and activity, whether a given treatment has a beneficial effect and how fast the patient can expect to see such effects, whether a patient should be given different or additional treatments.
Advancements in research and development contribute to the growth of the U.S. cellular immunotherapy market. Multiple therapeutic approaches and agents are currently being developed to manipulate many aspects of the immune system. Inhibitors of all checkpoints, cytokine therapies, monoclonal antibodies, adoptive cell therapies, cancer vaccines, and oncolytic viruses have all proven successful in clinical trials. R&D can lead to discoveries and ideas, or the invention or improvement of products and services. This helps organizations gain a competitive benefit and become the ‘go-to’ brand for a specific type of product. It can also lead to cost-efficient solutions for issues faced by companies. Also, it can pave the way to bring new products and services to market. Additionally, R&D can enhance a company’s brand value, broaden its value client base, and increase revenue.
According to the American Cancer Society report published in January 2025, the incidences of Non-Hodgkin Lymphoma,
Non-Hodgkin Lymphoma (NHL) is one of the most common cancers in the United States, accounting for about 4% of all cancers.
The American Cancer Society’s estimates for non-Hodgkin lymphoma in 2025 are:
Published by Ajit Bansod
